Plain-English translation of NCT07187531 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called SAB-142, which is designed to help slow down type 1 diabetes in people who were recently diagnosed. The study will compare the medication at different doses against placebo to see which works best and is safest. Researchers hope this treatment can help preserve the body's ability to produce insulin longer after diagnosis.
Type 1 diabetes develops when the immune system mistakenly attacks insulin-producing cells in the pancreas. This trial exists to see if this medication can calm that immune attack early on, potentially slowing the disease before too much damage occurs.
You likely qualify if…
You likely don't qualify if…
The study has three parts. In Part A, some participants receive the medication openly. In Part B, new participants are randomly assigned to receive either the medication (at high or low dose) or placebo, and neither they nor the researchers know who gets what. In Part C, eligible participants continue treatment long-term while researchers monitor their diabetes progression and health. Throughout, you'll have regular clinic visits for blood tests and check-ins, and participants wear a continuous glucose monitor to track blood sugar.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
United States